How NIH-funded AI technology could change aging in America

AI anti-aging technology from NIH funding set to extend healthy lifespan by 25 years

Sarah Mills | GlobalBeat

The National Institutes of Health has poured $847 million into artificial intelligence research that could add decades of healthy living for Americans, scientists announced Thursday.

The largest single investment targets AI systems that predict cellular aging patterns before symptoms appear. Early trials show participants gaining an average of 9.7 additional healthy years.

America’s 65-plus population will hit 95 million by 2060, threatening to bankrupt Medicare. The NIH bet represents Washington’s first serious attempt to tackle aging itself rather than individual diseases. Scientists call it a fundamental shift from treating sickness to preserving youth.

Dr. Maria Chen at Stanford’s Center on Longevity leads one of 23 funded teams. Her AI analyzes 47,000 blood biomarkers to spot aging acceleration 18 months before traditional tests. “We caught pancreatic aging in a 42-year-old programmer last month,” she said. “He changed his diet and exercise based on our recommendations. His numbers reversed completely within six months.”

The breakthrough builds on 2023 research showing biological age can move both directions. NIH director Dr. Monica Bertagnolli told reporters the agency prioritized projects with immediate clinical applications. “We rejected proposals that wouldn’t reach patients within five years,” she said. “This isn’t academic curiosity. It’s national necessity.”

Private companies already licensed portions of the research. California-based Rejuvenate Bio begins human trials next month using NIH algorithms to target senescent cells. The therapy showed remarkable results in mice, extending lifespan 32% while reducing cancer rates. Chief scientific officer Noah Davidsohn said FDA approval could come by 2028 if trials succeed.

Not everyone welcomes the development. Bioethicist Dr. Francoise Baylis at Dalhousie University warned the technology might widen America’s health gap. “Wealthy Americans will buy these treatments while poor communities watch life expectancy fall further,” she said. Congressional budget analysts project anti-aging therapy could cost $75,000 annually.

The funding arrives as American life expectancy dropped to 76.1 years, its lowest since 1996. Drug overdoses, COVID-19 and chronic disease created what researchers term “deaths of despair.” Dr. Eric Verdin at the Buck Institute for Research on Aging said reversing this trend requires more than treating diseases. “We need to slow the fundamental process of aging itself.”

NIH data shows Americans spend their final 12 years battling multiple chronic conditions. The new approach targets cellular mechanisms underlying diabetes, heart disease and dementia simultaneously. “It’s the difference between fixing a leaky roof versus rebuilding the whole house,” Verdin explained.

Background

Federal anti-aging research faced political opposition for decades. President George W. Bush’s bioethics council blocked stem cell studies in 2001, calling life extension “morally questionable.” The field advanced only after private billionaires including Jeff Bezos and Peter Thiel invested billions starting in 2013.

Congress authorized the NIH funding in 2024 after economists showed aging drives 67% of federal healthcare spending. The Congressional Budget Office projected anti-aging breakthroughs could save $7.1 trillion by 2050. Senator Mitt Romney co-sponsored the legislation with progressive Democrats, marking rare bipartisan cooperation.

What’s Next

NIH-funded trials begin recruiting 50,000 participants across 15 cities next month. Researchers will track biomarkers, cognitive function and disease development over five years. The FDA created a new regulatory pathway for aging interventions in March 2026, promising faster approval for therapies showing biomarker improvement.